CL2011001967A1 - Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. - Google Patents
Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.Info
- Publication number
- CL2011001967A1 CL2011001967A1 CL2011001967A CL2011001967A CL2011001967A1 CL 2011001967 A1 CL2011001967 A1 CL 2011001967A1 CL 2011001967 A CL2011001967 A CL 2011001967A CL 2011001967 A CL2011001967 A CL 2011001967A CL 2011001967 A1 CL2011001967 A1 CL 2011001967A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- inflammatory diseases
- azaheterocyclic
- cancer
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
LA PRESENTE INVENCIÓN DESCRIBE COMPUESTOS DERIVADOS DE AMINO CARBOXAMIDA AZAHETEROCÍCLICA SUSTITUIDA DE FÓRMULA (1), DONDE X, Y, R' Y R 2 SON COMO SE DEFINEN EN EL PLIEGO DE REIVINDICACIONES; ADICIONALMENTE SE DESCRIBE A LA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE A DICHOS COMPUESTOS; EL USO DE DICHOS COMPUESTOS EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS E INFLAMATORIAS, ENTRE OTRAS; AL PROCESO DE FABRICACIÓN DE LOS MISMOS; Y EL KIT QUE LOS COMPRENDE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20735409P | 2009-02-11 | 2009-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011001967A1 true CL2011001967A1 (es) | 2012-03-30 |
Family
ID=42199208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011001967A CL2011001967A1 (es) | 2009-02-11 | 2011-08-11 | Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. |
Country Status (26)
Country | Link |
---|---|
US (2) | US8637532B2 (es) |
EP (1) | EP2396307B1 (es) |
JP (1) | JP5642714B2 (es) |
KR (1) | KR101699991B1 (es) |
CN (1) | CN102317269B (es) |
AR (1) | AR075396A1 (es) |
AU (1) | AU2010214095B2 (es) |
BR (1) | BRPI1008325A2 (es) |
CA (1) | CA2751886C (es) |
CL (1) | CL2011001967A1 (es) |
DK (1) | DK2396307T3 (es) |
EA (1) | EA020731B1 (es) |
ES (1) | ES2527940T3 (es) |
HK (1) | HK1166070A1 (es) |
HR (1) | HRP20141239T1 (es) |
IL (1) | IL214412A0 (es) |
MX (1) | MX338354B (es) |
MY (1) | MY160468A (es) |
NZ (1) | NZ595087A (es) |
PL (1) | PL2396307T3 (es) |
PT (1) | PT2396307E (es) |
SG (1) | SG173473A1 (es) |
SI (1) | SI2396307T1 (es) |
UA (1) | UA107188C2 (es) |
WO (1) | WO2010093419A1 (es) |
ZA (1) | ZA201106624B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103140484B (zh) * | 2010-07-29 | 2015-04-22 | 默克专利有限公司 | 环状胺氮杂杂环甲酰胺 |
UA110113C2 (xx) * | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
US8946247B2 (en) | 2010-11-24 | 2015-02-03 | Merck Patent Gmbh | Quinazoline carboxamide azetidines |
ES2644536T3 (es) | 2011-09-12 | 2017-11-29 | Merck Patent Gmbh | Imidazol-aminas novedosas como moduladores de la actividad cinasa |
EP2755958B9 (en) | 2011-09-12 | 2018-02-28 | Merck Patent GmbH | Aminopyrimidine derivatives for use as modulators of kinase activity |
SG11201402387WA (en) * | 2011-12-22 | 2014-09-26 | Merck Patent Gmbh | Novel heterocyclic carboxamides as modulators of kinase activity |
ES2620119T3 (es) | 2012-11-16 | 2017-06-27 | Merck Patent Gmbh | Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa |
ES2807539T3 (es) | 2012-11-16 | 2021-02-23 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa |
KR20150090044A (ko) * | 2012-11-29 | 2015-08-05 | 메르크 파텐트 게엠베하 | 아자퀴나졸린 카복사미드 유도체 |
EP3632426A1 (en) | 2013-02-01 | 2020-04-08 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
MX370448B (es) | 2013-03-11 | 2019-12-13 | Merck Patent Gmbh | Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa. |
GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
RU2733401C2 (ru) | 2014-04-03 | 2020-10-01 | Мерк Патент Гмбх | Комбинации противораковых лекарств |
CN104292170B (zh) * | 2014-09-22 | 2016-06-29 | 广西师范大学 | 具有抗肿瘤作用的喹唑啉-芳基脲衍生物及其应用 |
CN107206004A (zh) * | 2014-10-22 | 2017-09-26 | 德克萨斯大学***董事会 | 靶向盘状结构域受体1的小分子抑制剂及其用途 |
GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
FR3066761B1 (fr) | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
WO2019006322A1 (en) * | 2017-06-30 | 2019-01-03 | The University Of North Carolina At Chapel Hill | HETEROCROMATINE GENE REPRESSION INHIBITORS |
ES2910071T3 (es) | 2018-03-08 | 2022-05-11 | Incyte Corp | Compuestos de aminopirazina diol como inhibidores de PI3K-Y |
TW202016076A (zh) | 2018-05-31 | 2020-05-01 | 南韓商C&C新藥研究所 | 雜環衍生物及其用途 |
CN109369634B (zh) * | 2018-12-19 | 2021-07-27 | 陕西国际商贸学院 | 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途 |
RU2723481C1 (ru) * | 2019-10-03 | 2020-06-11 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ УНИТАРНОЕ ПРЕДПРИЯТИЕ "ИНСТИТУТ ХИМИЧЕСКИХ РЕАКТИВОВ И ОСОБО ЧИСТЫХ ХИМИЧЕСКИХ ВЕЩЕСТВ НАЦИОНАЛЬНОГО ИССЛЕДОВАТЕЛЬСКОГО ЦЕНТРА "КУРЧАТОВСКИЙ ИНСТИТУТ" (НИЦ "Курчатовский институт - ИРЕА) | 4-[метил 4-(аминометил)циклогексанкарбоксилат]хиназолин и способ его получения |
AU2020372700A1 (en) | 2019-11-01 | 2022-05-12 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
CN112778217B (zh) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | 一种喹唑啉类化合物及其应用 |
US20240024324A1 (en) | 2020-11-16 | 2024-01-25 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
AU2022299145A1 (en) | 2021-06-24 | 2023-12-07 | Syngenta Crop Protection Ag | 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides |
WO2023201185A1 (en) * | 2022-04-11 | 2023-10-19 | Merck Patent Gmbh | Pyrido[3,2-d]pyrimidines as hpk1 inhibitors |
WO2023247360A1 (en) | 2022-06-21 | 2023-12-28 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
CN115521474B (zh) * | 2022-09-30 | 2023-08-22 | 陕西科技大学 | 一种基于五重互穿氢键有机框架材料及其制备方法和应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5651457A (en) * | 1979-09-14 | 1981-05-09 | Dev Finance | Antitumoral compound and its manufacture |
GB8804445D0 (en) * | 1988-02-25 | 1988-03-23 | Smithkline Beckman Intercredit | Compounds |
AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
RU2002110461A (ru) * | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
CN100345830C (zh) * | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
SK18102002A3 (sk) * | 2000-06-28 | 2003-07-01 | Astrazeneca Ab | Substituované chinazolínové deriváty, ich použitie a kompozícia obsahujúca tieto deriváty |
HU229477B1 (en) * | 2001-12-24 | 2014-01-28 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
AU2004278413B2 (en) | 2003-09-30 | 2008-07-31 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP1678168B1 (en) | 2003-10-24 | 2012-07-11 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
CN1902200A (zh) | 2003-11-21 | 2007-01-24 | 诺瓦提斯公司 | 用做蛋白激酶抑制剂的1h-咪唑并喹啉类衍生物 |
CA2546920A1 (en) | 2003-12-09 | 2005-06-23 | Joel Moss | Methods for suppressing an immune response or treating a proliferative disorder |
WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
ATE543821T1 (de) | 2004-12-28 | 2012-02-15 | Exelixis Inc | Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
EP1902032A1 (en) | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
CA2682504C (en) * | 2007-04-05 | 2012-10-30 | Amgen Inc. | Aurora kinase modulators and method of use |
UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
-
2010
- 2010-02-04 EA EA201101182A patent/EA020731B1/ru not_active IP Right Cessation
- 2010-02-04 AU AU2010214095A patent/AU2010214095B2/en active Active
- 2010-02-04 CN CN201080007165.1A patent/CN102317269B/zh active Active
- 2010-02-04 SI SI201030849T patent/SI2396307T1/sl unknown
- 2010-02-04 BR BRPI1008325-1A patent/BRPI1008325A2/pt not_active IP Right Cessation
- 2010-02-04 UA UAA201110411A patent/UA107188C2/ru unknown
- 2010-02-04 EP EP10705453.8A patent/EP2396307B1/en active Active
- 2010-02-04 KR KR1020117021335A patent/KR101699991B1/ko active IP Right Grant
- 2010-02-04 MY MYPI2011003710A patent/MY160468A/en unknown
- 2010-02-04 CA CA2751886A patent/CA2751886C/en active Active
- 2010-02-04 PT PT107054538T patent/PT2396307E/pt unknown
- 2010-02-04 DK DK10705453.8T patent/DK2396307T3/en active
- 2010-02-04 NZ NZ595087A patent/NZ595087A/xx unknown
- 2010-02-04 SG SG2011055001A patent/SG173473A1/en unknown
- 2010-02-04 WO PCT/US2010/000313 patent/WO2010093419A1/en active Application Filing
- 2010-02-04 JP JP2011550122A patent/JP5642714B2/ja active Active
- 2010-02-04 MX MX2011008395A patent/MX338354B/es active IP Right Grant
- 2010-02-04 PL PL10705453T patent/PL2396307T3/pl unknown
- 2010-02-04 ES ES10705453.8T patent/ES2527940T3/es active Active
- 2010-02-04 US US13/148,903 patent/US8637532B2/en active Active
- 2010-02-11 AR ARP100100376A patent/AR075396A1/es not_active Application Discontinuation
-
2011
- 2011-08-02 IL IL214412A patent/IL214412A0/en active IP Right Grant
- 2011-08-11 CL CL2011001967A patent/CL2011001967A1/es unknown
- 2011-09-09 ZA ZA2011/06624A patent/ZA201106624B/en unknown
-
2012
- 2012-07-10 HK HK12106745.1A patent/HK1166070A1/xx unknown
-
2013
- 2013-12-13 US US14/105,974 patent/US9040560B2/en active Active
-
2014
- 2014-12-19 HR HRP20141239AT patent/HRP20141239T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011001967A1 (es) | Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
UY31198A1 (es) | Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones. | |
UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
CR20110270A (es) | Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades | |
UY30748A1 (es) | Compuesto0s novedosos | |
PA8819201A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
CR20180339A (es) | INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576) | |
UY32494A (es) | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones | |
CL2012001971A1 (es) | Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras. | |
GT200600117A (es) | Nuevos compuestos farmaceuticos | |
UY32859A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
ECSP109903A (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
UY29803A1 (es) | Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones | |
PA8841901A1 (es) | Compuestos orgánicos | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
CR20120264A (es) | Compuestos | |
DOP2011000076A (es) | Derivados de heteroaril amidas y su uso como activadores de glucoquinasa | |
UY32918A (es) | Nuevos compuestos de 2-piridona | |
UY29767A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
DOP2006000017A (es) | Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso | |
UY33349A (es) | Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos |